AtriCure Inc logo

ATRCAtriCure Inc

NASDAQ · Healthcare · Medical Instruments & Supplies

$48.92

+$0.57 (+1.18%)

AtriCure Inc (ATRC) is a medical instruments & supplies company listed on NASDAQ. It is led by Michael H. Carrel, based in 7555 Innovation Way, Mason, OH, United States, 45040, with about 1,350 employees. AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; cryoXT probes, a cryoablation device designed specifically for Cryo Nerve Block therapy; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Latest reported ATRC revenue for 2025-09-30 was $134.3M. Net income was -$267.0K. Revenue was down 1.4% from 2025-06-30 to 2025-09-30. ATRC currently screens at market cap $1.37B.

Use this ATRC page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ATRC quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ATRC SEC filings page. Lician reads the product cache first so this HTML stays unique to AtriCure Inc even when a live quote feed is slow.

About AtriCure Inc

AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; cryoXT probes, a cryoablation device designed specifically for Cryo Nerve Block therapy; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

ATRC Key Statistics

Market Cap

$1.37B

Volume

859,640

Previous Close

$48.68

Day Range

$47.06$48.55

00

EPS

-$0.95

Revenue

$465.31M

Net Income

-$44.70M

Gross Profit

$0.00

Free Cash Flow

$0.00

Revenue Growth

+16.5%

Profit Margin

-9.6%

Employees

1,350

ATRC Financials

Annual income statement in USD. Latest reported periods first.

ATRC annual income statement across FY2024, FY2023, FY2022, FY2021
LineFY2024FY2023FY2022FY2021
Revenue$465.31M$399.25M$330.38M$274.33M
Cost of Revenue$0.00$0.00$0.00$0.00
Gross Profit$0.00$0.00$0.00$0.00
Operating Income$0.00$0.00$0.00$0.00
Net Income-$44.70M-$30.44M-$46.47M$50.20M
EPS (Diluted)-$0.95-$0.66-$1.02$1.09

Total Assets

$609.33M

Total Debt

$0.00

Shareholders' Equity

$0.00

Cash & Equivalents

$122.72M

Operating Cash Flow

$12.20M

Free Cash Flow

$0.00

AtriCure Inc Company Information

CEO, President & Director
Michael H. Carrel
Headquarters
7555 Innovation Way, Mason, OH, United States, 45040
Phone
513 755 4100
IPO / Founded
2005-08-05
Industry
Medical Instruments & Supplies
Data Updated:

Upcoming Events for ATRC